Abbvie Inc

NYSE:ABBV   3:04:03 PM EDT
+2.02 (+1.53%)

Abbvie Submits Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis To FDA And EMA

Published: 01/07/2022 14:26 GMT
Abbvie Inc (ABBV) - Abbvie Submits Applications for Upadacitinib (rinvoq®) in Non-radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (fda) and European Medicines Agency (ema).
Abbvie Inc - No New Safety Risks Were Observed Compared to Known Safety Profile of Upadacitinib.
Abbvie Inc - Submissions Supported by Phase 3 Study in Which Upadacitinib Demonstrated Significant Improvements in Signs and Symptoms.
Abbvie Inc - Also Submitted Results From Two Studies of Upadacitinib in Adult Patients With Ankylosing Spondylitis to Request Label Enhancements in Eu.